Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Champions Oncology (CSBR) Shares Outstanding (Weighted Average) (2016 - 2026)

Champions Oncology has reported Shares Outstanding (Weighted Average) over the past 16 years, most recently at $13.9 million for Q1 2026.

  • For Q1 2026, Shares Outstanding (Weighted Average) rose 1.95% year-over-year to $13.9 million; the TTM value through Jan 2026 reached $13.9 million, up 1.95%, while the annual FY2025 figure was $13.7 million, 0.83% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q1 2026 was $13.9 million at Champions Oncology, up from $13.8 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $13.9 million in Q1 2026 and troughed at $13.2 million in Q1 2022.
  • A 5-year average of $13.6 million and a median of $13.6 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): decreased 1.5% in 2022 and later rose 2.94% in 2023.
  • Year by year, Shares Outstanding (Weighted Average) stood at $13.5 million in 2022, then fell by 0.23% to $13.5 million in 2023, then rose by 0.72% to $13.6 million in 2024, then grew by 1.21% to $13.8 million in 2025, then rose by 0.93% to $13.9 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CSBR at $13.9 million in Q1 2026, $13.8 million in Q4 2025, and $13.8 million in Q3 2025.